Filing Flows › Comparisons › VISK vs ADPT
Viskase Holdings vs Adaptive Biotechnologies: VISK and ADPT compared
Viskase Holdings is the larger company: $95.3M of revenue in its latest quarter (Q3 2026) against $83.9M for Adaptive Biotechnologies (Q3 2026). Viskase Holdings is growing faster (+4% against -11% a year earlier). Adaptive Biotechnologies is more profitable, with an operating margin of -0.5% against -3.3%.
Where the money goes: VISK and ADPT
Viskase Holdings (VISK) · Q3 2026
Viskase Holdings, Q3 2026: revenue $95.3M (+4% year over year), operating margin -3.3%, net loss $6.4M, operating cash flow $454K. The chart follows the revenue to costs, profit and cash.
Adaptive Biotechnologies (ADPT) · Q3 2026
Adaptive Biotechnologies, Q3 2026: revenue $83.9M (-11% year over year), operating margin -0.5%, net earnings $2.8M, operating cash flow $9.6M. The chart follows the revenue to costs, profit and cash.
| Viskase Holdings (VISK) | Adaptive Biotechnologies (ADPT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $95.3M | $83.9M |
| Revenue growth, Y/Y | +4% | -11% |
| Operating margin | -3.3% | -0.5% |
| Net earnings | −$6.4M | $2.8M |
| Net margin | -6.8% | 3.3% |
| Operating cash flow | $454K | $9.6M |
| Free cash flow | — | $7.7M |
Where the revenue comes from
Viskase Holdings
- Nojax: $53.8M (57%)
- Fibrous: $22.5M (24%)
- Plastic: $10.7M (11%)
- Other: $3.3M (3%)
Questions
Which is bigger, Viskase Holdings or Adaptive Biotechnologies?
Viskase Holdings is the larger company: $95.3M of revenue in its latest quarter (Q3 2026) against $83.9M for Adaptive Biotechnologies (Q3 2026).
Is Viskase Holdings or Adaptive Biotechnologies growing faster?
Viskase Holdings is growing faster (+4% against -11% a year earlier).
Which is more profitable, Viskase Holdings or Adaptive Biotechnologies?
Adaptive Biotechnologies is more profitable, with an operating margin of -0.5% against -3.3%.
More: Viskase Holdings earnings · how Viskase Holdings makes money · Adaptive Biotechnologies earnings · how Adaptive Biotechnologies makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.